Mesoblast マネジメント

マネジメント基準チェック /24

Mesoblastの CEO はSilviu Itescuで、 Jan2004年に任命され、の在任期間は 20.83年です。の年間総報酬は$ 2.02Mで、 25%給与と75%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の6.92%を直接所有しており、その価値はA$ 126.73M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と7.2年です。

主要情報

Silviu Itescu

最高経営責任者

US$2.0m

報酬総額

CEO給与比率	25.0%
CEO在任期間	20.8yrs
CEOの所有権	6.9%
経営陣の平均在職期間	5.1yrs
取締役会の平均在任期間	7.2yrs

経営陣の近況

Recent updates

CEO報酬分析

Mesoblast の収益と比較して、Silviu Itescu の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	US$2m	US$505k	-US$88m
Mar 31 2024	n/a	n/a	-US$82m
Dec 31 2023	n/a	n/a	-US$73m
Sep 30 2023	n/a	n/a	-US$81m
Jun 30 2023	US$1m	US$673k	-US$82m
Mar 31 2023	n/a	n/a	-US$81m
Dec 31 2022	n/a	n/a	-US$84m
Sep 30 2022	n/a	n/a	-US$86m
Jun 30 2022	US$1m	US$697k	-US$91m
Mar 31 2022	n/a	n/a	-US$92m
Dec 31 2021	n/a	n/a	-US$97m
Sep 30 2021	n/a	n/a	-US$97m
Jun 30 2021	US$2m	US$757k	-US$99m
Mar 31 2021	n/a	n/a	-US$109m
Dec 31 2020	n/a	n/a	-US$98m
Sep 30 2020	n/a	n/a	-US$97m
Jun 30 2020	US$2m	US$697k	-US$78m
Mar 31 2020	n/a	n/a	-US$66m
Dec 31 2019	n/a	n/a	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	US$1m	US$709k	-US$90m
Mar 31 2019	n/a	n/a	-US$90m
Dec 31 2018	n/a	n/a	-US$86m
Sep 30 2018	n/a	n/a	-US$48m
Jun 30 2018	US$2m	US$748k	-US$35m

報酬と市場: Silviuの総報酬 ($USD 2.02M ) は、 Australian市場 ($USD 1.10M ) の同規模の企業の平均を上回っています。

報酬と収益: Silviuの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Silviu Itescu (67 yo)

20.8yrs

在職期間

US$2,017,166

報酬

Dr. Silviu Itescu, MBBS (Hons), FRACP, FACP, FACRA, FTSE has been the Chief Executive Officer and Managing Director of Mesoblast Limited since 2011. Prof. Itescu is the Chief Executive Officer at Mesoblast...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Silviu Itescu	Founder	20.8yrs	US$2.02m	6.92% A$ 126.7m
Eric Rose	Chief Medical Officer & Executive Director	2.8yrs	US$1.53m	0.036% A$ 660.7k
Andrew Chaponnel	Interim Chief Finance Officer	3.3yrs	データなし	データなし
Peter Howard	General Counsel & Corporate Executive	13.3yrs	データなし	データなし
Paul Simmons	Scientific Advisor to the Chief Executive Officer	13.8yrs	データなし	データなし
Geraldine Storton	Head of Regulatory Affairs & Quality Management	no data	データなし	データなし
Justin Horst	Head of Manufacturing	no data	データなし	データなし
Fiona See	Senior VP & Head of Translational Research	no data	データなし	データなし
Niva Sivakumar	Joint Company Secretary	5.1yrs	データなし	データなし
Paul Hughes	Joint Company Secretary	2.6yrs	データなし	データなし
Kenneth Borow	Executive	no data	データなし	データなし

5.1yrs

平均在職期間

67yo

平均年齢

経験豊富な経営陣: MSBの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Silviu Itescu	Founder	17.4yrs	US$2.02m	6.92% A$ 126.7m
Eric Rose	Chief Medical Officer & Executive Director	11.6yrs	US$1.53m	0.036% A$ 660.7k
Philip Facchina	Independent Non-Executive Director	3.7yrs	US$112.47k	0.011% A$ 197.8k
William A. Burns	Independent Non-Executive Vice Chairman	10.7yrs	US$134.05k	0.0093% A$ 170.5k
Henry Krum	Member of Scientific Advisory Board	no data	データなし	データなし
Joseph Lane	Member of Scientific Advisory Board	no data	データなし	データなし
Robert Graham	Member of Scientific Advisory Board	no data	データなし	データなし
Jane Bell	Independent Non-Executive Chairman	2.3yrs	US$153.70k	0.048% A$ 872.3k
Richard Gilbert	Member of Scientific Advisory Board	no data	データなし	データなし
Stephen Graves	Member of Scientific Advisory Board	no data	データなし	データなし
Philip Krause	Non-Independent Non Executive Director	2.7yrs	US$343.70k	0.025% A$ 461.4k

7.2yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: MSBの取締役会は経験豊富であると考えられます ( 7.2年の平均在任期間)。

Mesoblast マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Independent Non-Executive Director recently bought AU$200k worth of stock

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Forecast breakeven date pushed back to 2027

Full year 2024 earnings released: US$0.089 loss per share (vs US$0.11 loss in FY 2023)

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Independent Non-Executive Director recently bought AU$200k worth of stock

No longer forecast to breakeven

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

New minor risk - Share price stability

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

New major risk - Shareholder dilution

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

No longer forecast to breakeven

First half 2024 earnings released: US$0.038 loss per share (vs US$0.057 loss in 1H 2023)

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.14 loss in FY 2022)

New major risk - Share price stability

Forecast breakeven date pushed back to 2026

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Third quarter 2023 earnings released: US$0.025 loss per share (vs US$0.033 loss in 3Q 2022)

No longer forecast to breakeven

Second quarter 2023 earnings released: US$0.033 loss per share (vs US$0.04 loss in 2Q 2022)

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.035 loss in 1Q 2022)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Insider recently bought AU$111k worth of stock

Full year 2022 earnings released: US$0.14 loss per share (vs US$0.16 loss in FY 2021)

Mesoblast Limited Announces Board Changes

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Forecast to breakeven in 2025

Mesoblast Limited Provides Litigation Update

Third quarter 2022 earnings released: US$0.033 loss per share (vs US$0.044 loss in 3Q 2021)

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Mesoblast Limited Announces Executive Changes

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer

Forecast to breakeven in 2024

Mesoblast Limited Announces 36-Month Results of Phase 3 Trial in Chronic Low Back Pain

Mesoblast Provides Update Following Meeting with FDA’s OTAT on Remestemcel-L for Children with Acute Graft Versus Host Disease

No longer forecast to breakeven

Mesoblast Limited Receives Feedback from the US Food & Drug Administration’S Office of Tissues and Advanced Therapies on the Phase 3 Program of Rexlemestrocel-L

Insufficient new directors

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Mesoblast Limited announced that it expects to receive $90 million in funding from Oaktree Capital Management, L.P.

Forecast to breakeven in 2024

Full year 2021 earnings released: US$0.15 loss per share (vs US$0.15 loss in FY 2020)

Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference

Mesoblast Limited Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.044 loss per share (vs US$0.028 loss in 3Q 2020)

Forecast to breakeven in 2024

Mesoblast Limited Improves Outcomes in Inflammatory Lung Disease with Remestemcel-L Published in Respiratory Research Journal

Mesoblast Limited Announces the 60 Day Results from the Randomized Controlled Trial of remestemcel-L in 222 Ventilator-Dependent COVID-19 Patients with Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Which Had Been Halted After the Third Interim Analysis

Mesoblast Limited announced that it expects to receive AUD 138.251367 million in funding

Revenue beats expectations

マネジメント基準チェック /24